Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
Two large studies compared posaconazole and fluconazole or itraconazole for prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation or subjects with acute myelogenous leukemia. To assess the impact of prophylaxis on colonization and the development of resistance in Saccharomyces yeasts, identification and susceptibility testing were performed with yeasts cultured at regular intervals from mouth, throat, and stool samples. Prior to therapy, 34 to 50% of the subjects were colonized with yeasts. For all three drugs, the number of positive Candida albicans cultures decreased during drug therapy. In contrast, the proportion of subjects with positive C. glabrata cultures increased by two- and fourfold in the posaconazole and itraconazole arms, respectively. Likewise, in the fluconazole arm the proportion of subjects with positive C. krusei cultures increased twofold. C. glabrata was the species that most frequently exhibited decreases in susceptibility, and this trend did not differ significantly between the prophylactic regimens. For the subset of subjects from whom colonizing C. glabrata isolates were recovered at the baseline and the end of treatment, approximately 40% of the isolates exhibited more than fourfold increases in MICs during therapy. Molecular typing of the C. albicans and C. glabrata isolates confirmed that the majority of the baseline and end-of-treatment isolates were closely related, suggesting that they were persistent colonizers and not newly acquired. Overall breakthrough infections by Candida species were very rare (approximately 1%), and C. glabrata was the colonizing species that was the most frequently associated with breakthrough infections.
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Paul A
PA
Mann
Paul M
PM
McNicholas
Andrew S
AS
Chau
Reena
R
Patel
Cara
C
Mendrick
Andrew J
AJ
Ullmann
Oliver A
OA
Cornely
Hernando
H
Patino
Todd A
TA
Black
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002175:Candida / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D002176:Candida albicans / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D041221:Candida glabrata / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010802:Phylogeny; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D055815:Young Adult
D000935:Antifungal Agents; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D015725:Fluconazole